MediWound(NASDAQ) MDWD

Market Cap$161.90M

Since IPO (2014)-90%

5 Year-43%

1 Year-30%

1 Month-9%

$12.57

+1.21%

+0.15Today

After hours$12.56-$0.01 (-0.08%)

MediWound last closing stock price
Metric	Price	Date
Last close	USD 12.54	2026-10-09

MediWound stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.25%	USD 13.52	2026-10-02
1 month	-9.39%	USD 13.84	2026-09-09
3 month	-12.25%	USD 14.29	2026-07-10
Year to date	-32.07%	USD 18.46	2025-12-31
1 year	-29.94%	USD 17.90	2025-10-09
3 year	+34.12%	USD 9.35	2023-10-10
5 year	-43.49%	USD 22.19	2021-10-08
Since inception	-89.63%	USD 120.89	2014-03-20

MediWound Financials at a Glance

Market Cap

$161.90M

Revenue (TTM)

$11.86M

Net Income (TTM)

-$20.18M

EPS (TTM)

-$1.60

P/E Ratio

-7.82

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$12.57

Volume

92,645

Open

$12.42

Price

$12.57

Volume

92,645

Open

$12.42

Previous Close

$12.54

Daily Range

$12.42 - $13.15

52-Week Range

$12.42 - $20.03

Estimated Earnings Date

Nov 19, 2026

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$12.57

Volume

92,645

Open

$12.42

Previous Close

$12.54

Daily Range

$12.42 - $13.15

52-Week Range

$12.42 - $20.03

Estimated Earnings Date

Nov 19, 2026

MDWD News

MediWound Revenue Jumps 43% in Q2

Motley Fool Markets TeamAug 14, 2025

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

Leo SunMay 21, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediWound

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative bio-therapeutic solutions for tissue repair and regeneration. The company operates internationally, providing advanced treatments for chronic wounds and burns, with a commitment to improving patient outcomes.

Products and Services

NexoBrid: A biopharmaceutical product for eschar removal in burn patients
EscharEx: A bromelain-based therapy for chronic and hard-to-heal wounds
MW005: A biological product candidate for treating non-melanoma skin cancers

Growth Outlook

Recent quarterly revenue increased to $3.09 million, showing growth potential
Strong cash position with $43.44 million in cash and short-term investments
Ongoing development of innovative therapies positions the company for future market expansion

Financial Highlights

Trailing twelve months (TTM) revenue of $14.99 million indicates a solid market presence
Operating expenses for Q2 2026 were $9.8 million, reflecting ongoing investment in R&D
Net income for Q2 2026 was -$7.39 million, highlighting the need for continued financial management

AI Generated • Sep 26, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

121

CEO

Ofer Gonen

Website

www.mediwound.com

Headquarters

Yavne, HM 8122745, IL

MDWD Financials

Key Financial Metrics (TTM)

Gross Margin

15.46%

Operating Margin

-267.86%

Net Income Margin

-170.10%

Return on Equity

-47.24%

Return on Capital

-48.82%

Return on Assets

-28.07%

Earnings Yield

-12.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$161.90M

Shares Outstanding

12.91M

Volume

92.64K

Avg. Volume

84.80K

Financials (TTM)

Gross Profit

$1.83M

Operating Income

-$31.78M

EBITDA

-$19.00M

Operating Cash Flow

-$22.00M

Capital Expenditure

-$6.38M

Free Cash Flow

-$28.39M

Cash & ST Invst.

$35.34M

Total Debt

$9.54M

MediWound Performance Analysis

MediWound annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 26,496,000	11.5%
2023	2023-12-31	USD 18,686,000	-29.5%
2024	2024-12-31	USD 20,222,000	8.2%
2025	2025-12-31	USD 16,959,000	-16.1%

MediWound sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-4.9%
Q4	2025-12-31	-65.6%
Q1	2026-03-31	-21.0%
Q2	2026-06-30	109.6%

MediWound annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.93	12.9%
2023	2023-12-31	USD -0.75	-81.0%
2024	2024-12-31	USD -3.03	307.3%
2025	2025-12-31	USD -2.10	-30.8%

MediWound sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	80.5%
Q4	2025-12-31	-133.3%
Q1	2026-03-31	58.9%
Q2	2026-06-30	-147.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$3.09M

-45.8%

Gross Profit

$337.00K

-74.9%

Gross Margin

10.90%

N/A

Market Cap

$161.90M

N/A

Market Cap/Employee

$1.34M

N/A

Employees

121

N/A

Net Income

-$7.39M

+44.5%

EBITDA

-$9.06M

-85.1%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$35.34M

+9.0%

Total Debt

$9.54M

+7.3%

Accounts Receivable

$3.49M

-48.6%

Inventory

$4.12M

+7.1%

Long Term Debt

$8.61M

+6.6%

Short Term Debt

$932.00K

+13.4%

Return on Assets

-28.07%

N/A

Return on Invested Capital

-59.58%

N/A

Free Cash Flow

-$10.06M

-47.8%

Operating Cash Flow

-$8.99M

-56.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IVAInventiva S.A.

IVAInventiva S.A.$3.16-4.82%

TARAProtara Therapeutics, Inc.

TARAProtara Therapeutics, Inc.$2.76+3.96%

RNACCartesian Therapeutics, Inc.

RNACCartesian Therapeutics, Inc.$7.06+3.45%

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.72+2.97%

AARDAardvark Therapeutics, Inc. Common Stock

AARDAardvark Therapeutics, Inc. Common Stock$4.76+1.06%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$7.46-1.45%

NTHINeonc Technologies Holdings, Inc.

NTHINeonc Technologies Holdings, Inc.$2.78+9.88%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$22.18-9.81%

WFFWf

WFFWf$12.29+499.51%

VZVerizon Communications

VZVerizon Communications$41.65-8.75%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$162.57+1.25%

NVDANvidia

NVDANvidia$229.28-0.52%

VEEAVeea

VEEAVeea$5.70+47.29%

NUNu Holdings

NUNu Holdings$16.12+4.81%

Questions About MDWD

What is the current price of MediWound?

MediWound is trading at $12.54 per share.

What is the 52-week range for MediWound?

Over the past 52 weeks, MediWound has traded between $12.42 and $20.03.

How much debt does MediWound have?

As of the most recent reporting period, MediWound reported total debt of $9.54M.

How much cash does MediWound have on hand?

MediWound reported $4.34M in cash and cash equivalents in its most recent financial results.

What is MediWound’s dividend yield?

MediWound does not currently have a dividend yield.

MediWound(NASDAQ) MDWD

MediWound Financials at a Glance

MDWD News

MediWound Revenue Jumps 43% in Q2

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MediWound

MDWD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MediWound Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MDWD

What is the current price of MediWound?

What is the 52-week range for MediWound?

How much debt does MediWound have?

How much cash does MediWound have on hand?

What is MediWound’s dividend yield?

Premium Investing Services